Literature DB >> 8403506

Measurement of antiphospholipid antibody by ELISA using purified beta 2-glycoprotein I in preeclampsia.

T Yamamoto1, S Yoshimura, Y Geshi, Y Sasamori, S Okinaga, T Kobayashi, H Mori.   

Abstract

It has been reported that the binding of some antiphospholipid antibodies (APA) to phospholipids requires the presence of beta 2-glycoprotein I (beta 2-GPI). Using a new ELISA, in which well coated phospholipids were treated with a constant amount of purified beta 2-GPI, we tried to detect the presence of APA which binds to phospholipid/beta 2-GPI complex or to phospholipids such as cardiolipin (CA) and phosphatidylserine (PS) in preeclampsia, and to check for clinical abnormalities in antibody-positive cases. Serum samples were taken from 43 cases of preeclampsia, including 26 cases of the severe type, and 47 normal pregnant women. Positive rates of anticardiolipin antibody (ACA) by ELISA using CA/beta 2-GPI complex in mild, severe and total preeclampsia were 20.0, 17.4% and 18.4% respectively. No antibody-positive cases were found in normal pregnancies. ACA was detected much more frequently when cardiolipin/beta 2-GPI complex was used in ELISA compared with ELISA without beta 2-GPI. Positive rates of antiphosphatidylserine antibody (APSA) in mild, severe and total preeclampsia were 5.9%, 11.5% and 9.3% respectively. APSA was also detected much more frequently when the phosphatidylserine/beta 2-GPI complex was used in ELISA. The frequency of intrauterine growth retardation (IUGR) in the ACA-positive subjects was higher than that of ACA negatives. We suggest that the ACA and APSA which bind to phospholipid/beta 2-GPI complex are detectable in preeclampsia, and that these antiphospholipid antibodies are related to fetal growth.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8403506      PMCID: PMC1534358          DOI: 10.1111/j.1365-2249.1993.tb06000.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  19 in total

1.  Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor.

Authors:  M Galli; P Comfurius; C Maassen; H C Hemker; M H de Baets; P J van Breda-Vriesman; T Barbui; R F Zwaal; E M Bevers
Journal:  Lancet       Date:  1990-06-30       Impact factor: 79.321

2.  Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment.

Authors:  F S Cowchock; E A Reece; D Balaban; D W Branch; L Plouffe
Journal:  Am J Obstet Gynecol       Date:  1992-05       Impact factor: 8.661

Review 3.  Antiphospholipid antibodies and recurrent pregnancy loss.

Authors:  D A Triplett
Journal:  Am J Reprod Immunol       Date:  1989-06       Impact factor: 3.886

4.  Clinical significance, prevalence, and natural history of thrombocytopenia in pregnancy-induced hypertension.

Authors:  R Romero; M Mazor; C J Lockwood; M Emamian; K P Belanger; J C Hobbins; T Duffy
Journal:  Am J Perinatol       Date:  1989-01       Impact factor: 1.862

5.  Arterial thrombosis, intrauterine death and "lupus" antiocoagulant: detection of immunoglobulin interfering with prostacyclin formation.

Authors:  L O Carreras; G Defreyn; S J Machin; J Vermylen; R Deman; B Spitz; A Van Assche
Journal:  Lancet       Date:  1981-01-31       Impact factor: 79.321

6.  beta 2-Glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway.

Authors:  I Schousboe
Journal:  Blood       Date:  1985-11       Impact factor: 22.113

7.  Prothrombinase activity of human platelets is inhibited by beta 2-glycoprotein-I.

Authors:  J Nimpf; E M Bevers; P H Bomans; U Till; H Wurm; G M Kostner; R F Zwaal
Journal:  Biochim Biophys Acta       Date:  1986-10-29

8.  Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H).

Authors:  H P McNeil; R J Simpson; C N Chesterman; S A Krilis
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

9.  The association of antiphospholipid antibodies with severe preeclampsia.

Authors:  D W Branch; R Andres; K B Digre; N S Rote; J R Scott
Journal:  Obstet Gynecol       Date:  1989-04       Impact factor: 7.661

10.  Obstetric complications associated with the lupus anticoagulant.

Authors:  D W Branch; J R Scott; N K Kochenour; E Hershgold
Journal:  N Engl J Med       Date:  1985-11-21       Impact factor: 91.245

View more
  3 in total

Review 1.  Antiphospholipid Antibodies Increase the Risk of Fetal Growth Restriction: A Systematic Meta-Analysis.

Authors:  Jinfeng Xu; Daijuan Chen; Yuan Tian; Xiaodong Wang; Bing Peng
Journal:  Int J Clin Pract       Date:  2022-01-31       Impact factor: 3.149

2.  Role of reactive oxygen species in gynecologic diseases.

Authors:  Rakesh K Sharma; Ashok Agarwal
Journal:  Reprod Med Biol       Date:  2004-12-03

Review 3.  Do antiphospholipid antibodies cause preeclampsia and HELLP syndrome?

Authors:  Erin A S Clark; Robert M Silver; D Ware Branch
Journal:  Curr Rheumatol Rep       Date:  2007-06       Impact factor: 4.686

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.